地舒单抗纳入医保了吗

Giant cell tumor of bone is an extremely rare and rapidly progressing primary bone tumor rich in human nuclear factor activator ligand (RANKL), manifesting as eccentric bony lesions in the metaphysis and epiphysis of long bones or the spine and sacrum. The lesion appears as a highly vascularized and aggressive bony lesion with indistinct borders and a wide transition zone. RANKL-expressing mononuclear stromal cells are the tumor component of giant cell tumor of bone lesions, and based on current hypotheses, their role is to recruit osteoclast-like giant cells, causing the tumor to have aggressive osteolytic activity.

In May 2019, Angavir (desosomeumab) received marketing approval from the National Medical Products Administration for the treatment of giant cell tumors of bone that are unresectable or that surgical resection may cause severe dysfunction. The approval of Angarvi marks that the treatment of giant cell tumor of bone has moved from relatively single treatments such as surgery and radiotherapy to the era of drug treatment. The diagnosis and treatment of giant cell tumor of bone has officially realized comprehensive joint treatment among internal medicine, surgery and other departments. As the only bone-targeted drug currently approved in China, Angavir (desosomeumab) has been recommended as a cornerstone in the "Chinese Society of Clinical Oncology Giant Cell Tumor of Bone (CSCO GCTB) Diagnosis and Treatment Guidelines" released this time, bringing new treatment options and new hope to patients who suffer from this rare disease but are limited by current treatment options.

At present, the more common domestic versions include the domestic version, the Taiwan version, the European Turkish version, and the Indian and Bangladeshi version. Due to regional differences in the prices of these types of denosumab, domestic tariffs and various taxes lead to different prices. The price in Taiwan is about NT$12,500 equivalent to RMB 3,000, the European Turkish version is less than RMB 2,000, and the Bangladeshi version is even more favorable. Domestic denosumab has not yet been included in the medical insurance, so it needs to be paid for at your own expense, and the price is 5,298$ per injection. However, I believe that in the near future, with the development of science and technology, denosumab will appear in the medical insurance sooner or later, bringing more convenience to the people.